Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Classical hematology 1Breast 1

Conditions

Solid Tumor 1Neoplasms 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Long-Term Synaptic Depression × 1 year × Clear all
NCT06711523 2025-11-25

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Kexing Biopharm Co., Ltd.

Phase 3 Active not recruiting
250 enrolled
Classical hematology

Chemotherapy-Induced Febrile Neutropenia

NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting
1,039 enrolled
Breast

Breast Neoplasms

NCT06055179 2025-07-01

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Guangzhou University of Traditional Chinese Medicine

Phase NA Recruiting
98 enrolled
Tumor-Agnostic

Neoplasms

NCT07030439 2025-06-22

A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State

Impact Therapeutics, Inc.

Phase 1 Completed
32 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡